Leuprolide (Androgen Deprivation Therapy - ADT)
Treatment for Prostate Cancer
Typical Dosage: 7.5 mg IM monthly, or 22.5 mg IM every 3 months
Effectiveness
75%
Safety Score
62%
Clinical Trials
79
Participants
300K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
62
DangerousModerateSafe
Treatment Details
Dosage Range
7.5 mg IM monthly, or 22.5 mg IM every 3 months
Time to Effect
1-3 months (clinical effects)
Treatment Duration
Years to lifetime
Evidence Quality
HIGHConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$4,800
Monitoring:$800
Side Effect Mgmt:$400
Total Annual:$6,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$25,000/QALY
QALYs Gained
2.5
Outcome-Based Costs
Cost per Responder
$8,000
Leuprolide (Androgen Deprivation Therapy - ADT) Outcomes
for Prostate Cancer
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+75%
Common Side Effects
Hot flashes
+65%
Fatigue
+55%
Decreased libido/erectile dysfunction
+85%
Bone density loss/osteoporosis
+40%
Weight gain
+20%
Cardiovascular events (long-term)
+10%
Sources:
Active Clinical Trials
8 active trials recruiting for Leuprolide (Androgen Deprivation Therapy - ADT) in Prostate Cancer
Short Course ADT for High Risk Low/Intermediate Risk ARTERA Prostate Cancer
NCT07801664RECRUITINGPHASE2
90 participants
INTERVENTIONAL
New York, United States
Started: Aug 6, 2026
Real-life Evaluation of the Effect of ADT in Prostate Cancer Patients in Asia (READT Asia Study)
NCT03703778ACTIVE NOT RECRUITING
300 participants
OBSERVATIONAL
Shatin, Hong Kong
Started: May 22, 2016
Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer
NCT05628363ACTIVE NOT RECRUITINGNA
28 participants
INTERVENTIONAL
St Louis, United States
Started: Jan 18, 2023
Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)
NCT06654336RECRUITINGPHASE2
162 participants
INTERVENTIONAL
Hamilton, Canada +2 more
Started: May 6, 2026
ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer
NCT02972060ACTIVE NOT RECRUITINGPHASE2
61 participants
INTERVENTIONAL
Brussels, Belgium +11 more
Started: Dec 1, 2017
Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT07389187NOT YET RECRUITINGEARLY_PHASE1
10 participants
INTERVENTIONAL
Shanghai, China
Started: Feb 1, 2026
Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer
NCT03511196ACTIVE NOT RECRUITINGEARLY_PHASE1
17 participants
INTERVENTIONAL
Tampa, United States
Started: Sep 17, 2018
Trial Evaluating the Safety and Efficacy Of MR-Linac-Guided Radiotherapy as Salvage Treatment After External Beam Radiotherapy Recurrence (TUMORNATOR II)
NCT07142967RECRUITINGNA
28 participants
INTERVENTIONAL
New York, United States
Started: Aug 15, 2025
Completed Clinical Trials
10 completed trials for Leuprolide (Androgen Deprivation Therapy - ADT) in Prostate Cancer
A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan
NCT04034095COMPLETED
979 participants
OBSERVATIONAL
Akita, Japan +76 more
Started: Jul 8, 2019
Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT
NCT03007732COMPLETEDPHASE2
23 participants
INTERVENTIONAL
San Francisco, United States
Started: May 17, 2017
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
NCT01546987COMPLETEDPHASE3
239 participants
INTERVENTIONAL
Birmingham, United States +171 more
Started: May 1, 2012
Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy
NCT02217566COMPLETEDPHASE2
46 participants
INTERVENTIONAL
Porto Alegre, Brazil +3 more
Started: Sep 23, 2014
A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer
NCT02059213COMPLETEDPHASE2
72 participants
INTERVENTIONAL
Duarte, United States +7 more
Started: Jun 1, 2014
PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer
NCT02472275COMPLETEDPHASE1
8 participants
INTERVENTIONAL
Detroit, United States +2 more
Started: Jun 1, 2015
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
NCT01431391COMPLETEDPHASE2
68 participants
INTERVENTIONAL
Homewood, United States +13 more
Started: Sep 1, 2011
Initiation of Androgen Deprivation Therapy for Prostate Cancer Using Degarelix Followed by Leuprolide
NCT01344564COMPLETEDNA
50 participants
INTERVENTIONAL
Virginia Beach, United States
Started: Apr 1, 2011
Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)
NCT02057939COMPLETEDPHASE2
38 participants
INTERVENTIONAL
New Brunswick, United States +2 more
Started: Apr 1, 2014
Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
NCT00776594COMPLETEDPHASE2
102 participants
INTERVENTIONAL
Baltimore, United States +7 more
Started: Oct 1, 2008
Showing 20 of 89 total trials